THC Global has signed a deal with Medleaf Therapeutics for the production and supply of pharmaceutical medicinal cannabis in New Zealand.
Under the arrangement, THC will produce white-labelled medicinal cannabis for Medleaf to supply, with the first medicines rolled out in October 2020 following registration.
An initial order of 2,250 bottles of Full Spectrum CBD and Balanced THC:CBD medicines has been placed, with the initial production agreement running until August 2021 and automatically renewed annually thereafter.
Medleaf was established in 2018 and has become a major supplier of cannabis medicines in New Zealand. It has a well-established supply chain across the country, rapidly increasing sales in the last two years, and strong relationships in the patient advocacy community.
NZ’s Medicinal Cannabis Scheme came into effect on April 1 with GPs given the green light to prescribe medicinal cannabis. Companies are also able to apply for licences to cultivate, manufacture and distribute products.
THC Global will seek registration before supplying to Medleaf.
Medleaf Therapeutics CEO Courtney Letica said: “The new cannabis medicine regulations in New Zealand are a significant opportunity for established brands to reach more patients in need who may benefit from medicinal cannabis. We look forward to working with New Zealand doctors to make cannabis medicines more accessible for New Zealanders.”
THC Global CEO Ken Charteris added: “We are very pleased to be working with Medleaf as one of New Zealand’s leading cannabis medicine brands, and look forward to working together on providing choice in high quality, affordable medicinal cannabis to patients in New Zealand.”